GLP-1s for Prediabetes and Weight Loss: What the Evidence Suggests

Prediabetes is a warning that blood glucose is above the normal range, not a guarantee that type 2 diabetes will develop. For some adults who also meet criteria for obesity treatment, GLP-1–based medicines can support substantial weight loss and improve glucose measures. The important distinction is why the medicine is being prescribed: prediabetes alone is not the same thing as an automatic indication for a weight-management drug. [1] [2] [6] [7]

First, what counts as prediabetes?

The CDC defines the A1C prediabetes range as 5.7% to 6.4%. A fasting blood glucose of 100 to 125 mg/dL is also in the prediabetes range. These tests measure different aspects of glucose regulation, and a clinician may repeat or confirm an unexpected result—especially when anemia, kidney disease, pregnancy, recent blood loss, or another condition could affect interpretation. [1]

Prediabetes describes risk, not destiny. Risk varies with the actual glucose value, body weight, age, family history, prior gestational diabetes, activity level, sleep, medications, and other health conditions. That is why two people with the same A1C may receive different plans. [2]

If you want a plain-language refresher on the drug class, start with Yucca’s guide to how GLP-1 medications work. The rest of this article focuses on what prediabetes trials can—and cannot—tell you.

Why weight loss changes the conversation

Excess adiposity can worsen insulin resistance and increase the chance that prediabetes progresses. The 2026 ADA Standards recommend structured prevention support for adults at high risk, with goals that include weight loss and maintenance, slowing hyperglycemia, and addressing cardiovascular risk. They also emphasize that treatment intensity should reflect individual risk rather than one lab number. [2]

GLP-1 receptor agonists such as semaglutide reduce appetite and energy intake through several physiologic pathways. Tirzepatide acts at both GIP and GLP-1 receptors. In obesity trials, these medicines were studied as additions to nutrition and physical-activity support—not as replacements for those supports. [6] [7]

Weight-management eligibility is separate from the prediabetes label. Yucca’s GLP-1 eligibility guide explains the usual BMI and comorbidity framework in more detail.

What semaglutide studies found

STEP 10 enrolled 207 adults with obesity and prediabetes and compared semaglutide 2.4 mg with placebo, alongside diet and physical-activity counseling. At 52 weeks, mean weight change was −13.9% with semaglutide and −2.7% with placebo. Among participants with glucose data, 81% in the semaglutide group and 14% in the placebo group met that trial’s definition of normoglycemia. [3]

The trial was relatively small, lasted one year on treatment, and used glucose thresholds defined in its protocol. It shows that semaglutide can improve weight and glycemic status in a selected obesity-and-prediabetes population; it does not prove that every person with prediabetes should take semaglutide. [3]

A separate analysis of the large SELECT cardiovascular-outcomes trial found that semaglutide increased regression to biochemical normoglycemia and reduced progression to biochemical diabetes in adults with overweight or obesity and established cardiovascular disease but no diabetes. The authors also reported that semaglutide did not change the underlying rate of glycemic progression over time—a reminder that crossing a diagnostic threshold and changing the disease process are not identical claims. [5]

What tirzepatide studies found

The three-year SURMOUNT-1 analysis followed 1,032 participants who had both obesity and prediabetes. At week 176, mean weight change ranged from −12.3% to −19.7% across tirzepatide doses, compared with −1.3% for placebo. Type 2 diabetes was diagnosed in 1.3% of tirzepatide-treated participants and 13.3% of placebo participants during the 176-week treatment period. [4]

After a 17-week off-treatment period, diabetes had been diagnosed in 2.4% of participants originally assigned to tirzepatide and 13.7% assigned to placebo. That follow-up supports a strong treatment-period effect, but it also reinforces a practical point: long-term outcomes after discontinuation are not fully answered by the trial, and obesity medicines are generally planned as chronic therapy when effective and tolerated. [4] [2]

What the evidence does not mean

• It does not mean prediabetes alone automatically qualifies someone for Wegovy or Zepbound. Their current U.S. weight-management indications center on obesity or overweight with at least one weight-related comorbid condition. [6] [7]
• It does not prove that a temporary return to the normal glucose range permanently removes diabetes risk. Ongoing weight, glucose, and cardiovascular-risk monitoring still matter. [2] [5]
• It does not establish that one medicine is best for every person. STEP 10 and SURMOUNT-1 were different trials with different populations, durations, and methods; their percentages are not a head-to-head comparison. [3] [4]
• It does not erase treatment burdens. Gastrointestinal effects are common, contraindications and warnings apply, costs and coverage vary, and benefits may diminish after treatment stops. [6] [7] [4]

Who might discuss a GLP-1 medicine with a clinician?

A useful starting question is not “Is my A1C high enough for a GLP-1?” but “Do I meet criteria for obesity treatment, and how does my prediabetes change the expected benefit?” Current Wegovy and Zepbound labels include adults with obesity, or adults with overweight plus at least one weight-related comorbid condition, when used with reduced-calorie eating and increased physical activity. The clinician must still decide whether a specific product is appropriate. [6] [7]

ADA guidance highlights more intensive prevention for people at particularly high risk, including those with BMI at least 35 kg/m², higher fasting glucose or A1C within the prediabetes range, or a history of gestational diabetes. It specifically recommends considering metformin for selected high-risk adults and recognizes weight-management pharmacotherapy as part of individualized care for people with overweight or obesity. [2]

A clinician should also review pregnancy plans, pancreatitis or gallbladder history, kidney function, gastrointestinal disease, personal or family history relevant to the boxed thyroid-tumor warning, and medicines that can affect glucose or cause hypoglycemia. The labels—not social-media dosing schedules—set the safety boundaries. [6] [7]

What to ask at an appointment

1. Was the prediabetes result confirmed, and which test should we follow over time? [1]
2. Do I meet the labeled criteria for weight-management medication, independent of the prediabetes result? [6] [7]
3. What is my estimated risk of progression based on A1C or fasting glucose, BMI, age, family history, and prior gestational diabetes? [2]
4. Would a structured diabetes-prevention program, metformin, obesity pharmacotherapy, or a combination fit my risk and goals? [2]
5. How will we monitor weight, A1C or fasting glucose, side effects, nutrition, and other cardiometabolic risk factors? [2]
6. What is the long-term plan if the medicine works—and what should we expect if access or treatment stops? [4] [2]

Regular movement remains part of the prevention plan, including when medication is used. For practical context, see Yucca’s guide to exercise while using a GLP-1 medicine.

The bottom line

The evidence is encouraging: in selected adults with obesity and prediabetes, semaglutide and tirzepatide produced substantial weight loss and improved glucose outcomes compared with placebo. The strongest interpretation is that effective obesity treatment can lower near-term diabetes risk—not that one prediabetes result is a universal prescription for a GLP-1 medicine. [3] [4] [5] [2]

Confirm the diagnosis, estimate your overall risk, and discuss the full menu of prevention options. If a GLP-1–based medicine fits, agree on what success means, how safety and nutrition will be monitored, and what the long-term plan is before the first dose. [1] [2] [6] [7]